Table 1.
Somatic mutational burden per tumor type. In theory, tumor-specific neoantigen generation and presentation is directly proportional to mutational burden.
| Disease | Somatic mutation prevalence (average number mutations per megabase) | Formation of Neoantigens |
|---|---|---|
| Melanoma | ∼20 | Frequently |
| Lung Squamous | ∼9.5 | Regularly |
| Lung Adeno | ∼9.0 | Regularly |
| Stomach | ∼8.5 | Regularly |
| Esophagus | ∼8.0 | Regularly |
| Lung Small Cell | ∼8.0 | Regularly |
| Colorectal | ∼8.0 | Regularly |
| Bladder | ∼7.5 | Regularly |
| Uterus | ∼7.0 | Regularly |
| Cervix | ∼6.5 | Regularly |
| Liver | ∼6.0 | Regularly |
| Head and Neck | ∼5.0 | Regularly |
| Kidney Clear Cell | ∼2.0 | Regularly |
| Lymphoma B-Cell | ∼1.5 | Regularly |
| Kidney Papillary | ∼1.1 | Regularly |
| Breast | ∼1.0 | Occasionally |
| Pancreas | ∼1.0 | Occasionally |
| Myeloma | ∼1.0 | Occasionally |
| Ovary | ∼1.0 | Occasionally |
| Prostate | ∼1.0 | Occasionally |
| Glioblastoma | ∼0.9 | Occasionally |
| Glioma Low Grade | ∼0.85 | Occasionally |
| Neuroblastoma | ∼0.8 | Occasionally |
| Medulloblastoma | ∼0.7 | Occasionally |
| CLL | ∼0.65 | Occasionally |
| Kidney Chromophobe | ∼0.6 | Occasionally |
| Thyroid | ∼0.5 | Occasionally |
| ALL | ∼0.3 | Occasionally |
| AML | ∼0.2 | Occasionally |
| Pilocytic Astrocytoma | ∼0.05 | Occasionally |